文拉法辛联合喹硫平治疗重度抑郁症急性期患者的疗效观察

高丹青, 马笑风

高丹青, 马笑风. 文拉法辛联合喹硫平治疗重度抑郁症急性期患者的疗效观察[J]. 实用临床医药杂志, 2020, 24(1): 62-65. DOI: 10.7619/jcmp.202001016
引用本文: 高丹青, 马笑风. 文拉法辛联合喹硫平治疗重度抑郁症急性期患者的疗效观察[J]. 实用临床医药杂志, 2020, 24(1): 62-65. DOI: 10.7619/jcmp.202001016
GAO Danqing, MA Xiaofeng. Effect observation of venlafaxine combined with quetiapine in the treatment of patients with severe depression in acute phase[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 62-65. DOI: 10.7619/jcmp.202001016
Citation: GAO Danqing, MA Xiaofeng. Effect observation of venlafaxine combined with quetiapine in the treatment of patients with severe depression in acute phase[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 62-65. DOI: 10.7619/jcmp.202001016

文拉法辛联合喹硫平治疗重度抑郁症急性期患者的疗效观察

详细信息
    通讯作者:

    马笑风, E-mail: mxf1985@qq.com

  • 中图分类号: R749.4

Effect observation of venlafaxine combined with quetiapine in the treatment of patients with severe depression in acute phase

  • 摘要: 目的 探讨文拉法辛联合喹硫平治疗重度抑郁症急性期患者的临床效果。 方法 将100例重度抑郁症患者随机分为观察组与对照组,观察组给予文拉法辛联合喹硫平,对照组给予文拉法辛联合安慰剂。治疗4、8周后,比较2组汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评分,并应用药物副反应量表(TESS)评估药物的安全性。 结果 2组患者治疗前HAMD及HAMA评分比较无显著差异(P>0.05)。治疗4、8周后, 2组患者的HAMD及HAMA评分较治疗前显著降低(P<0.05), 且观察组治疗4周的HAMD及HAMA评分显著低于对照组(P<0.05)。治疗4周后,观察组疗效显著优于对照组(P<0.05)。治疗8周后,观察组疗效优于对照组,但差异无统计学意义(P>0.05)。治疗4、8周后, 2组患者的TESS评分比较,差异无统计学意义(P>0.05), 但治疗8周后的TESS评分低于治疗4周后,差异有统计学意义(P<0.05)。治疗4、8周后,观察组失眠及高血压发生例数少于对照组,差异有统计学意义(P<0.05)。 结论 文拉法辛联合喹硫平治疗重度抑郁症急性期患者安全、有效,可降低HAMD及HAMA评分,降低失眠及高血压的发生率。
    Abstract: Objective To explore the clinical effect of venlafaxine combined with quetiapine in the treatment of patients with severe depression in the acute phase. Methods A total of 100 patients with severe depression were randomly divided into observation group and control group. The observation group was treated with venlafaxine and quetiapine, while the control group was treated with venlafaxine and placebo. After 4 and 8 weeks of treatment, the scores of Hamilton Depression Scale(HAMD)and Hamilton Anxiety Scale(HAMA)were compared between two groups, and the safety of the drugs was assessed by Treatment Emergent Symptom Scale(TESS). Results There were no significant differences in HAMD and HAMA scores between the two groups before treatment(P>0.05). After 4 and 8 weeks of treatment, the scores of HAMD and HAMA in both groups were significantly lower than those before treatment(P<0.05), and the scores of HAMD and HAMA in the observation group were significantly lower than those in the control group(P<0.05). After 4 weeks of treatment, the effect of the observation group was significantly better than that of the control group(P<0.05). After 8 weeks of treatment, the effect of the observation group was better than that of the control group, but no significant difference was found(P>0.05). After 4 and 8 weeks of treatment, there was no significant difference in TESS score between the two groups(P>0.05), TESS score were lower at the 8th week when compared with the data at the 4th week(P<0.05). After 4 and 8 weeks of treatment, the number of patients with insomnia and hypertension in the observation group - was significantly less than that in the control group(P<0.05). Conclusion Venlafaxine combined with quetiapine is effective and safe in the treatment of patients with acute severe depression in acute phase, which can reduce scores of HAMD and HAMA, and incidence rate of insomnia and hypertension.
  • 王小丽. 益生菌治疗抑郁症的研究进展[J]. 神经疾病与精神卫生, 2017, 17(7): 525-527.
    李谨, 汪水利, 李云庆, 等. 抑郁症易感基因的研究进展[J]. 神经解剖学杂志, 2017, 33(1): 103-106.

    Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience[J]. World J Psychiatry, 2015, 5(3): 330-341.

    慕磊, 孙建绪. 抑郁症发病机制与抗抑郁药物作用靶标[J]. 国际药学研究杂志, 2015, 42(4): 463-466.

    Sie S D, Wennink J M, van Driel J J, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation[J]. Arch Dis Child Fetal Neonatal Ed, 2012, 97(6): F472-F476.

    姜美俊. 抗精神病药联合抗抑郁药治疗伴有精神病性症状的抑郁症1例[J]. 中国神经精神疾病杂志, 2017, 43(3): 190-192.

    Montgomery S A, Altamura A C, Katila H, et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels[J]. Int Clin Psychopharmacol, 2014, 29(2): 93-105.

    张华, 庞剑月, 曹素霞, 等. 认知行为治疗在抑郁症患者自杀态度安全管理中的应用[J]. 医学与哲学(B), 2018, 39(11): 80-82.
    相燕静, 王中刚, 陈景清. 单胺氧化酶抑制剂在精神科临床应用的研究进展[J]. 医学与哲学(B), 2016, 37(4): 54-57.
    宋婷婷, 周东晨, 吴丽鑫, 等. 从单胺机制分析抑郁症与癌症的关联[J]. 现代肿瘤医学, 2018, 26(22): 3686-3689.

    Locher M C, Koechlin M H, Zion M S R, et al. Efficacy and Safety of SSRIs, SNRIs, and Placebo in Common Psychiatric Disorders: A Comprehensive Meta-Analysis in Children and Adolescents[J]. Jama Psychiatry, 2017, 74(10): 1011-1011.

    翟金国, 赵靖平. 新型抗抑郁药治疗焦虑谱系障碍研究进展[J]. 中国药学杂志, 2007, 42(14): 1041-1045.
    侯霖, 李彦华, 王景俊. 抗抑郁药的研究新进展[J]. 医学综述, 2007, 13(19): 1511-1512.
    王玉文, 宋明芬. 度洛西汀与文拉法辛治疗抑郁症疗效和安全性的Meta分析[J]. 中国药师, 2016, 19(1): 96-99.
    罗新, 崔凤伟, 陆伟琦. 文拉法辛缓释胶囊与舍曲林治疗抑郁症的临床疗效和安全性对照研究[J]. 山西医药杂志, 2015, 44(12): 1392-1394.
    李力, 高睿哲, 杨壮凤, 等. 富马酸喹硫平对肺癌患者相关焦虑与抑郁的治疗效果[J]. 中国药物与临床, 2019, 19(2): 254-255.

    McIntyre R S, Filteau M J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach[J]. J Affect Disord, 2014, 156: 1-7.

    汪广阔. 奥氮平联合盐酸氟西汀治疗重度抑郁症急性期对生存质量的影响[J]. 中国医药指南, 2014, 12(35): 89-90.
  • 期刊类型引用(4)

    1. 曾海燕,杨小林. CT能谱参数对结直肠癌病理类型鉴别的价值. 中外医学研究. 2024(09): 64-67 . 百度学术
    2. 王海波,段宏伟,左自军,丁琦峰,张鹏辉. 术前能谱CT多参数成像对晚期肺癌患者淋巴结转移的预测价值. 河南医学研究. 2024(06): 1071-1074 . 百度学术
    3. 刘贲,张楠,邓治平. miR-126及Th1相关细胞因子在非小细胞肺癌患者血清中的表达水平及临床意义. 热带医学杂志. 2024(08): 1154-1158 . 百度学术
    4. 周宇元. 增强CT联合能谱CT预测肺癌患者淋巴结转移的临床分析. 江西医药. 2024(07): 676-679 . 百度学术

    其他类型引用(0)

计量
  • 文章访问数:  915
  • HTML全文浏览量:  461
  • PDF下载量:  29
  • 被引次数: 4
出版历程
  • 收稿日期:  2019-10-16
  • 网络出版日期:  2020-12-22
  • 发布日期:  2020-08-06

目录

    /

    返回文章
    返回